Crossover Backing Has Little-To-No Impact On Post-IPO Performance
This article was originally published in Start Up
Executive Summary
Based on a review of recent biotech IPOs, biopharma companies with crossover investors experienced virtually the same step-up in valuation as those firms without crossover backers, and only slightly higher average stock prices six months post-IPO.